Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors
- PMID: 12861106
- DOI: 10.1097/01.md.0000085057.63483.9b
Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors
Abstract
Numerous medications, including drugs prescribed for noncardiac indications, can lead to QT prolongation and trigger torsade de pointes. Although this complication occurs only rarely, it may have lethal consequences. It is therefore important to know if patients with torsade de pointes associated with noncardiac drugs have risk factors that are easy to identify. We reviewed reports of drug-induced torsade de pointes and analyzed each case of torsade de pointes associated with a noncardiac drug for the presence of risk factors for the long QT syndrome that can be easily identified from the medical history or clinical evaluation (female gender, heart disease, electrolyte disturbances, excessive dosing, drug interactions, and history of familial long QT syndrome). We identified 249 patients with torsade de pointes caused by noncardiac drugs. The most commonly identified risk factor was female gender (71%). Other risk factors were frequently present (18%-41%). Virtually all patients had at least 1 of these risk factors, and 71% of patients had 2 or more risk factors. Our study suggests that almost all patients with torsade de pointes secondary to noncardiac drugs have risk factors that can be easily identified from the medical history before the initiation of therapy with the culprit drug.
Similar articles
-
Long QT syndrome caused by noncardiac drugs.Prog Cardiovasc Dis. 2003 Mar-Apr;45(5):415-27. doi: 10.1053/pcad.2003.00101. Prog Cardiovasc Dis. 2003. PMID: 12704598 Review.
-
Drug-induced long QT syndrome and torsade de pointes.Can J Cardiol. 2005 Aug;21(10):857-64. Can J Cardiol. 2005. PMID: 16107909 Review.
-
Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.Acta Psychiatr Scand. 2005 Mar;111(3):171-6. doi: 10.1111/j.1600-0447.2004.00469.x. Acta Psychiatr Scand. 2005. PMID: 15701100 Review.
-
A case series of drug-induced long QT syndrome and Torsade de Pointes.Singapore Med J. 2001 Dec;42(12):566-70. Singapore Med J. 2001. PMID: 11989578
-
Drug-induced long QT and torsade de pointes: recent advances.Curr Opin Cardiol. 2007 Jan;22(1):39-43. doi: 10.1097/HCO.0b013e32801129eb. Curr Opin Cardiol. 2007. PMID: 17143043 Review.
Cited by
-
Cholinesterase inhibitors-associated torsade de pointes/QT prolongation: a real-world pharmacovigilance study.Front Pharmacol. 2024 Jan 11;14:1343650. doi: 10.3389/fphar.2023.1343650. eCollection 2023. Front Pharmacol. 2024. PMID: 38273821 Free PMC article.
-
Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.Clin Res Cardiol. 2009 Apr;98(4):208-12. doi: 10.1007/s00392-008-0741-y. Epub 2008 Nov 24. Clin Res Cardiol. 2009. PMID: 19031039
-
Synthetic cannabinoids and potential cardiac arrhythmia risk: an important message for drug users.Ther Adv Drug Saf. 2020 Mar 24;11:2042098620913416. doi: 10.1177/2042098620913416. eCollection 2020. Ther Adv Drug Saf. 2020. PMID: 32269749 Free PMC article. No abstract available.
-
Evaluating the prescribing and monitoring of medications associated with QTc-prolongation in the ambulatory care setting.J Eval Clin Pract. 2024 Apr;30(3):385-392. doi: 10.1111/jep.13949. Epub 2023 Dec 10. J Eval Clin Pract. 2024. PMID: 38073034 Free PMC article.
-
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.Circulation. 2010 Mar 2;121(8):1047-60. doi: 10.1161/CIRCULATIONAHA.109.192704. Epub 2010 Feb 8. Circulation. 2010. PMID: 20142454 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical